CT-125A

N/A

Report date: 2024/11/15 20:00:35

Base Information

Drug NameCT-125A
Drug Alias NameCT-125ARD-125
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell surface glycoprotein CD5 inhibitors
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, T-Cell, PeripheralLymphoma, T-Cell +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaDiscontinued
Originator CompaniesNanjing Iaso Biotherapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHuazhong University Of Science And Technology
Inactive CompaniesBeijing Gao Boren Hospital Co LtdShanghai Iaso Biotechnology Co Ltd
Active IndicationsLymphoma, T-Cell, PeripheralPlasmablastic Lymphoma
Inactive IndicationsHematologic NeoplasmsLymphoma, T-CellLymphoma, Mantle-Cell +[7] 

Other Information

ATC CodeN/A
Related LinksN/A